(NASDAQ: NUVL) Nuvalent's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 82.88%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.63%.
Nuvalent's revenue in 2025 is $0.On average, 7 Wall Street analysts forecast NUVL's revenue for 2026 to be $1,337,905,251, with the lowest NUVL revenue forecast at $306,445,557, and the highest NUVL revenue forecast at $4,369,553,122. On average, 5 Wall Street analysts forecast NUVL's revenue for 2027 to be $10,179,760,888, with the lowest NUVL revenue forecast at $2,848,141,062, and the highest NUVL revenue forecast at $18,225,218,600.
In 2028, NUVL is forecast to generate $26,635,238,368 in revenue, with the lowest revenue forecast at $11,111,355,382 and the highest revenue forecast at $34,503,606,601.